文献速递慢性肾脏病血液净化与透析

盐皮质激素受体拮抗剂在糖尿病合并慢性肾脏病中的肾脏与心脏保护作用

Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

糖尿病肾病患者即使接受RAS阻断剂与SGLT2抑制剂联合治疗,肾衰竭和心血管死亡风险仍高。甾体类MRA可降低白蛋白尿和心血管替代指标但高钾血症风险限制使用;非甾体类MRA非奈利酮在FIDELIO-DKD研究中减少DKD进展和心血管事件且不良事件相对安全。本文详述MRA心肾保护证据、机制及未来在糖尿病CKD治疗中的地位。

要点

  • 糖尿病合并CKD患者即使接受RAS阻断剂和SGLT2抑制剂联合治疗,肾衰竭和心血管死亡风险仍高。
  • 甾体类MRA可降低白蛋白尿和心血管替代指标,但高钾血症风险限制其使用。
  • 非奈利酮在FIDELIO-DKD研究中减少DKD进展和心血管事件,不良事件相对安全。

核心结论

  • 非奈利酮在FIDELIO-DKD研究中减少DKD进展和心血管事件,且不良事件相对安全。
  • MRA在优化治疗基础上仍具心肾保护潜力,但需权衡高钾血症风险。

研究设计与样本

  • 综述类文章,汇总MRA心肾保护证据并分析机制及未来地位。
  • 提及FIDELIO-DKD研究比较非奈利酮与安慰剂。

主要发现

  • 糖尿病肾病患者约40%的糖尿病患者发生,是全球CKD最常见病因。
  • CKD尤其合并糖尿病患者肾衰竭和心血管死亡风险高。
  • RAS阻断剂减少DKD肾衰竭基于≥20年前研究。
  • SGLT2抑制剂在随机试验中显示肾脏获益。
  • RAS阻断剂联合SGLT2抑制剂后肾脏残余风险仍高,肾衰竭仅延迟未避免。

临床怎么用

  • 糖尿病合并CKD患者即使接受RAS阻断剂和SGLT2抑制剂联合治疗,仍应考虑MRA以进一步降低心肾风险。
  • 使用MRA时需监测高钾血症风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diabetic kidney disease (DKD) develops in ∼40% of patients with diabetes and is the most common cause of chronic kidney disease (CKD) worldwide. Patients with CKD, especially those with diabetes mellitus, are at high risk of both developing kidney failure and cardiovascular (CV) death. The use of renin-angiotensin system (RAS) blockers to reduce the incidence of kidney failure in patients with DKD dates back to studies that are now ≥20 years old. During the last few years, sodium-glucose co-transporter-2 inhibitors (SGLT2is) have shown beneficial renal effects in randomized trials. However, even in response to combined treatment with RAS blockers and SGLT2is, the renal residual risk remains high with kidney failure only deferred, but not avoided. The risk of CV death also remains high even with optimal current treatment. Steroidal mineralocorticoid receptor antagonists (MRAs) reduce albuminuria and surrogate markers of CV disease in patients already on optimal therapy. However, their use has been curtailed by the significant risk of hyperkalaemia. In the FInerenone in reducing kiDnEy faiLure and dIsease prOgression in DKD (FIDELIO-DKD) study comparing the actions of the non-steroidal MRA finerenone with placebo, finerenone reduced the progression of DKD and the incidence of CV events, with a relatively safe adverse event profile. This document presents in detail the available evidence on the cardioprotective and nephroprotective effects of MRAs, analyses the potential mechanisms involved and discusses their potential future place in the treatment of patients with diabetic CKD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Ortiz A, Ferro CJ, Balafa O, et al. Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. Nephrol Dial Transplant. 2023. PMID: 33944938. doi:10.1093/ndt/gfab167

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。